Sponsored
Jeplus.in
Purchase All Medicines.Get 10% Offer
Pharma Tech
ESC 2026: oral and injectable GLP-1 comparisons under the spotlight
At ESC 2026, a session presented by Dr Domenica Rubino covered the considerations to take into account when comparing oral and injectable formulations of GLP-1 therapies.
Read Full Article
Pharma Tech
GSK licenses HUTCHMED’s solid tumour conjugate in up to $1.3bn deal
HMPL-A830 is an antibody-targeted therapy conjugate (ATTC) that selectively delivers a therapeutic drug to cancer cells, while sparing healthy tissue.
Read Full Article
Pharma Tech
Typewriter raises $56m Series A to progress non-viral gene therapy platform
Typewriter harnesses a non-viral approach as viral vectors increasingly come under the spotlight for their associated safety risks.
Read Full Article
Express Pharma
ABB’s Machine Automation division (B&R) appoints Christian Strahberger as Division PresidentÂ
ABB’s Machine Automation Division (B&R) today announced the appointment of Christian Strahberger as its new Division President. Christian Strahberger succeeds Florian Schneeberger, who tragically passed away in an accident in […] The post ABB’s Machine Automation division (B&R) appoints Christian Strahberger as Division President appeared first on Express Pharma.
Read Full Article
Pharma Tech
Biocytogen and Qilu Pharmaceutical sign agreement for VHH antibody molecule
Biocytogen Pharmaceuticals has entered into a non-exclusive licensing agreement with Qilu Pharmaceutical for a fully human VHH antibody molecule.
Read Full Article
Sponsored content
Featured promotional
News
Latest stories
ET Pharma
Sep 4, 2026, 2:47 AM
HUTCHMED signs licensing deal with GSK for experimental solid tumour drug
Clinical development ​for HMPL-A830 will focus initially on "colorectal, pancreatic and lung cancer ​indications", HUTCHMED said in a filing to the Hong Kong stock exchange.
ET Pharma
Sep 4, 2026, 2:44 AM
Cohance to acquire controlling stake in ADC manufacturers Aruka Bio, NJ Bio for $18 Mn
NJ Bio’s founder Dr. Naresh Jain, will continue to lead the company with 32.7 per cent shareholding and will also spearhead Aruka’s pipeline and partnership initiatives.
ET Pharma
Sep 4, 2026, 12:02 AM
Cipla licenses China's Qilu Pharmaceutical Keytruda biosimilar US rights
Pembrolizumab, marketed by US giant Merck (known as MSD in India) under the brand name Keytruda is world’s top selling immunotherapy, which clocked over $31 billion in 2025.
ET Pharma
Sep 3, 2026, 10:57 PM
Drug Makers Refuse to Bear Responsibility of Overpricing
The Federation of Pharma Entrepreneurs (FOPE) raised concerns that exempting downstream sellers entirely could open the door to disputes and pressure tactics against manufacturers.
Pharma Tech
Sep 3, 2026, 2:04 PM
ESC 2026: oral and injectable GLP-1 comparisons under the spotlight
At ESC 2026, a session presented by Dr Domenica Rubino covered the considerations to take into account when comparing oral and injectable formulations of GLP-1 therapies.
PharmaShots
Sep 3, 2026, 12:30 PM
Biogen and Eisai Report NMPA Approval of Leqembi (SC) as an Initiation Dose for Early Alzheimer’s Disease
Shots: Ref: Globenewswire |  Image: Biogen & Eisai  | Press Release PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com The post Biogen and Eisai Report NMPA Approval of Leqembi (SC) as an Initiation Dose for Early Alzheimer’s Disease appeared first on PharmaShots.
News
Latest industry coverage
Google News
Sep 4, 2026, 3:24 AM
Hope sells: inroads in cancer treatment excite markets - Al Majalla
Hope sells: inroads in cancer treatment excite markets  Al Majalla
Google News
Sep 4, 2026, 1:42 AM
How Gelomics is Redefining Cancer Drug Discovery - blog.google
How Gelomics is Redefining Cancer Drug Discovery  blog.google
Google News
Sep 4, 2026, 1:38 AM
Ultragenyx Pharmaceutical (RARE) Reports 61% Cornstarch Reduction In 96 Week Phase 3 Data - simplywall.st
Ultragenyx Pharmaceutical (RARE) Reports 61% Cornstarch Reduction In 96 Week Phase 3 Data  simplywall.st
Google News
Sep 4, 2026, 1:38 AM
Amneal Pharmaceuticals (AMRX) Following Its Biosimilars Push And The Fair Value Debate - simplywall.st
Amneal Pharmaceuticals (AMRX) Following Its Biosimilars Push And The Fair Value Debate  simplywall.st
Google News
Sep 4, 2026, 1:37 AM
IQVIA's Predictive Clinical Development Provides Sponsors With Significant Efficiencies to Get Treatments to Market Faster - BioSpace
IQVIA's Predictive Clinical Development Provides Sponsors With Significant Efficiencies to Get Treatments to Market Faster  BioSpace
Google News
Sep 4, 2026, 1:02 AM
Friday Five – Novartis draws BTK battle lines, hitting brakes on CAR-T, Trump's murky MFN markdowns…and more - FirstWord Pharma
Friday Five – Novartis draws BTK battle lines, hitting brakes on CAR-T, Trump's murky MFN markdowns…and more  FirstWord Pharma
Google News
Sep 4, 2026, 12:29 AM
Pakistan pharma industry opposes proposal to alter the drug pricing formula - Business Recorder
Pakistan pharma industry opposes proposal to alter the drug pricing formula  Business Recorder
Google News
Sep 4, 2026, 12:00 AM
A city that keeps reinventing its industrial DNA - The Hindu
A city that keeps reinventing its industrial DNAÂ Â The Hindu
Google News
Sep 3, 2026, 10:57 PM
Drug Makers Refuse to Bear Responsibility of Overpricing - pharma.economictimes.indiatimes.com
Drug Makers Refuse to Bear Responsibility of Overpricing  pharma.economictimes.indiatimes.com
Sponsored placement
Featured promotions
Sponsored
Jeplus.in
Purchase All Medicines.Get 10% Offer